Neuren Pharmaceuticals Limited (ASX: NEU)

Australia flag Australia · Delayed Price · Currency is AUD
19.90
-0.20 (-1.00%)
Jul 3, 2024, 4:10 PM AEST
70.09%
Market Cap 2.54B
Revenue (ttm) 231.93M
Net Income (ttm) 157.08M
Shares Out 127.27M
EPS (ttm) 1.20
PE Ratio 16.61
Forward PE 38.46
Dividend n/a
Ex-Dividend Date n/a
Volume 284,327
Open 20.17
Previous Close 20.10
Day's Range n/a
52-Week Range 10.02 - 25.95
Beta 2.03
Analysts n/a
Price Target 28.56 (+43.52%)
Earnings Date Jul 29, 2024

About Neuren Pharmaceuticals

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A.
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol NEU
Full Company Profile

Financial Performance

In 2023, NEU's revenue was 231.93 million, an increase of 1493.66% compared to the previous year's 14.55 million. Earnings were 157.08 million, an increase of 85270.11%.

Financial Statements

News

There is no news available yet.